Related Experiment Video
Updated: May 24, 2026
06:35
Sodium Taurocholate Induced Severe Acute Pancreatitis in C57BL/6 Mice
Published on: June 28, 2021
Liraglutide-associated acute pancreatitis
Emily Knezevich1, Theresa Crnic, Scott Kershaw
1School of Pharmacy and Health Professions, Creighton University, Omaha, NE 68178, USA. eknezevich@creighton.edu
Summary
A patient with type 2 diabetes developed acute pancreatitis after their liraglutide dosage was increased. This case highlights a potential adverse effect of liraglutide, a medication used for diabetes management.
Area of Science:
- Endocrinology
- Gastroenterology
Background:
- Liraglutide is a glucagon-like peptide-1 receptor agonist used for type 2 diabetes management.
- Acute pancreatitis is a serious inflammatory condition of the pancreas.
Observation:
- A 53-year-old male with type 2 diabetes presented with acute, severe abdominal pain, nausea, and elevated serum amylase and lipase levels.
- The patient's medical history included hyperlipidemia, hypertension, and obesity. His medications included liraglutide, metformin, simvastatin, tadalafil, and glimepiride.
- Liraglutide dosage was recently increased from 0.6 mg to 1.2 mg subcutaneously daily two months prior to presentation.
Findings:
- Acute pancreatitis was diagnosed based on clinical presentation, laboratory values, and radiographic data.
- Elevated triglycerides were ruled out as the cause of pancreatitis.
- Liraglutide was discontinued, leading to complete resolution of symptoms and normalization of laboratory values.
Implications:
- This case suggests a potential association between liraglutide use, particularly at higher doses, and the development of acute pancreatitis.
- Clinicians should consider liraglutide-induced pancreatitis in patients with type 2 diabetes presenting with compatible symptoms.
- Further investigation into the risk of liraglutide-associated pancreatitis is warranted.
More Related Videos
04:14Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis (NASH) Resolution
Published on: April 16, 2019
07:38Preparing a Mice Model of Severe Acute Pancreatitis via a Combination of Caerulein and Lipopolysaccharide Intraperitoneal Injection
Published on: May 10, 2024
Related Concept Videos
01:25Acute Pancreatitis I: Introduction
Acute pancreatitis is the sudden inflammation of the pancreas caused by the early activation of digestive enzymes, leading to the autodigestion of pancreatic tissue. This results in local inflammation and, in severe cases, systemic complications.EtiologyUnderstanding the underlying causes is crucial, as identifying the etiology guides treatment and anticipates complications. Acute pancreatitis can be triggered by various factors, typically grouped into the following clinical categories.Biliary...
01:27Acute Pancreatitis I: Introduction
Pancreatitis is inflammation of the pancreas, an organ located behind the stomach. It can be either acute or chronic.
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
01:30Acute Pancreatitis II: Clinical Manifestations and Management
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:21Acute Pancreatitis II: Pathophysiology
The pathophysiology of acute pancreatitis centers on injury to pancreatic acinar cells, which initiates a cascade of harmful intracellular events.This injury leads to premature activation of trypsinogen to trypsin in the pancreas. Trypsin then activates other digestive enzymes, such as chymotrypsin, elastase, and phospholipase A2, which begin breaking down pancreatic tissue. The resulting autodigestion causes local inflammation, tissue swelling, hemorrhage, and fat necrosis.Injured acinar cells...
01:25Chronic Pancreatitis I: Introduction
Chronic pancreatitis is a long-standing, relapsing inflammation of the pancreas, characterized by irreversible damage to the gland. It results in progressive destruction of the pancreatic parenchyma, fibrosis, and eventual loss of both exocrine and endocrine function. The disease may evolve gradually after multiple episodes of acute pancreatitis or develop independently.EtiologyChronic pancreatitis can arise from a variety of causes:Alcohol use is the leading cause, accounting for 70–80% of...